July 30, 2014 6:24 PM ET


Company Overview of EPIRUS Biopharmaceuticals, Inc.

Company Overview

EPIRUS Biopharmaceuticals, Inc. develops, manufactures, and commercializes biosimilar products. The company offers monoclonal antibodies and therapeutic proteins. Its products include BOW015, a monoclonal antibody against tumor necrosis factor alpha. The company’s product is used to treat autoimmune diseases. It serves customers in the United States and internationally. EPIRUS Biopharmaceuticals, Inc. was formerly known as fourteen22, Inc. and changed its name to EPIRUS Biopharmaceuticals, Inc. in January 2013. The company was incorporated in 2011 and is based in Boston, Massachusetts.

699 Boylston Street

11th Floor

Boston, MA 02116

United States

Founded in 2011



Key Executives for EPIRUS Biopharmaceuticals, Inc.

EPIRUS Biopharmaceuticals, Inc. does not have any Key Executives recorded.

EPIRUS Biopharmaceuticals, Inc. Key Developments

EPIRUS Biopharmaceuticals, Inc. Announces New Board Appointments

EPIRUS Biopharmaceuticals, Inc. reported that Mark Corrigan, Julie McHugh, and William Hunter will serve on its board of directors. The board was reconstituted following the company's merger with Zalicus Inc. It also includes Amit Munshi, Geoffrey Duyk, Scott Rocklage, Kevin Buchi and Daotian Fu. Corrigan will serve as the chairman of the Epirus board. Corrigan served as a director and was the president and chief executive officer of Zalicus from 2010 to 2014. McHugh will serve on the Epirus board as a director and member of the Audit and Compensation Committees. McHugh recently served as chief operating officer for Endo Health Solutions, Inc., where she was responsible for the specialty pharmaceutical and generic drug businesses. Hunter will serve on the Epirus board as a director and member of the Audit and Governance Committees. He is the president and chief executive officer of Cardiome Pharma Corp.

EPIRUS Biopharmaceuticals, Inc.(NasdaqCM:EPRS) added to NASDAQ Composite Index

EPIRUS Biopharmaceuticals, Inc will be added to the NASDAQ Composite Index.

EPIRUS Biopharmaceuticals, Inc. Announces Management Changes

On July 15, 2014, EPIRUS Biopharmaceuticals Inc., formerly known as Zalicus Inc. completed its merger with the former entity EPIRUS Biopharmaceuticals Inc. Pursuant to the terms of the Merger Agreement, effective immediately prior to the consummation of the Merger on July 15, 2014, Frank Haydu, Sally W. Crawford, Michael Kauffman and W. James O'Shea resigned from the company's board of directors. and J. Kevin Buchi, Geoffrey Duyk, Daotian Fu, Julie McHugh, Amit Munshi and Scott Rocklage were appointed as directors of the Company. Pursuant to the terms of the Merger Agreement, effective immediately after the consummation of the Merger on July 15, 2014, Mark H.N. Corrigan was terminated without cause from his position as President and Chief Executive Officer of the company, and Justin Renz was terminated without cause from his position as Executive Vice President, Chief Financial Officer, Treasurer and Secretary of the company. Amit Munshi was appointed as the company's President and Chief Executive Officer and Thomas Shea was appointed as the company's Chief Financial Officer.

Similar Private Companies By Industry

Company Name Region
Arcadia Biosciences, Inc. United States
Corridor Pharmaceuticals, Inc. United States
Boval Company, LP United States
Laser Isotope Enrichment Laboratory United States
nanoRETE, Inc. United States

Recent Private Companies Transactions

April 16, 2014
Zalicus Inc.
Private Placement
April 16, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EPIRUS Biopharmaceuticals, Inc., please visit www.epirusbiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.